Cancer Gene Therapy Market: Global Industry Analysis, Size, Share, and Forecasts 2024

Market Study Report adds a new Having endorsed itself as a one of the most remunerative verticals of the overall healthcare fraternity, cancer gene therapy market is practically transforming the way cancer diagnostics is being delivered in the recent years for the period of 2016-2024 that shows the growth of the market is rising at a Steady CAGR to 2024.

Cancer Gene Therapy Market size is expected to exceed USD 4.3 billion by 2024; as per a new research report.

Globally, rising cancer prevalence will increase demand for gene therapy as the effective personalized treatment choice. According to WHO, cancer incidence is projected to rise by 50% to reach 15 million by the end of this decade. This alarming increase in number of patients necessitates this as a potential treatment approach addressing the growing global burden of the disease.

Increased adoption of emerging genomic technologies such as NGS and high density micro array coupled with favorable government initiatives will fuel global cancer gene therapy market size. For instance, CDC supports nationwide screening programs for control of breast, cervical and colorectal cancer among low-income women with little or no health insurance. However, high cost of development lack of reimbursement and regulatory processes will restrain industry growth.

Growing number of clinical trials and availability of wide range of genes and vectors used in these trials will enable emergence of new treatment modalities to help make cancer a manageable disease. By the end of 2012, the number of clinical trials crossed 1,800 worldwide.

Request a sample of this premium report at: https://www.marketstudyreport.com/request-a-sample/467801/

Key insights from the report include:

U.S. cancer gene therapy market share accounted for over 95% regional revenue in 2015, with market size of USD 235 million and a forecast to grow at 20.9% CAGR.

UK was over USD 92.0 million in 2015, and will grow at 20.8% CAGR owing to increasing incidence of cancer and adoption of advanced treatment methods.

China market size was valued at USD 99.6 million in 2015 and growth expectations of 21% CAGR over the forecast years.

Key players include SiBiono, Altor Bioscience Corporation, Shanghai Sunway Biotech company limited, Amgen, BioCancell, OncoGeneX, Aduro Biotech, GlobeImmune, Inc., New Link Genetics., ZioPharm Oncology, MolMed, GENELUX, Gradalis, MultiVir.

The industry is highly fragmented and is dominated by several small biotech firms collectively accounting for over 80% of cancer gene therapy market pipeline. Major growth strategies adopted by these small firms include, technology transfer, licensing and commercialization deals, strategic collaborations and mergers and acquisitions to retain their industry position.

Request a discount on standard prices of this premium report at: https://www.marketstudyreport.com/check-for-discount/467801/

Selected points from Table of Contents of this report:

Chapter 1. Methodology and Scope
1.1. Research Methodology
1.1.1. Initial data exploration
1.1.2. Statistical modeling and forecast
1.1.3. Industry insights and validation
1.1.4. Research scope & assumptions
1.2. Data Sources
Chapter 2. Executive Summary
2.1. Cancer genetics industry 360 degree synopsis, 2012 - 2024
2.1.1. Business trends
2.1.2. Regional trends
2.1.3. Application trends
Chapter 3. Cancer Gene Therapy Industry Insights
3.1. Industry segmentation
3.2. IIndustry Size and forecast, 2012 - 2024
3.3. Industry Impact forces
3.3.1. Growth drivers
3.3.1.1. Technological advancements
3.3.1.2. Increased adoption of nanotechnology
3.3.1.3. Favorable government regulations
3.3.2. Industry pitfalls & challenges
3.3.2.1. High cost of cancer genetherapy
3.4. Growth potential analysis
3.5. Porter's analysis
3.6. Key opportunities prioritized, 2015
3.7. PESTEL analysis
3.8. Regulatory Landscape
3.8.1. U.S.
3.8.2. EU
3.8.3. China
3.9. Scientific and Ethical issues in Gene Therapy
3.10. Competitive landscape, 2015
3.11. Pipeline Analysis by cancer type
3.11.1. Head and Neck Cancer Pipeline Analysis
3.11.2. Breast Cancer Pipeline Analysis
3.11.3. Gastro Intestinal Cancer Pipeline Analysis
3.11.4. Gentiourinary Cancer Pipeline Analysis
3.11.5. Gynecological Cancer Pipeline Analysis
3.11.6. Haemotological Cancer Pipeline Analysis
3.11.7. Neurologic Cancer Pipeline Analysis
3.11.8. Respiratory Cancer Pipeline Analysis
3.11.9. Skin Cancer Pipeline Analysis

Outside scope of this report Quite overtly, cancer prevention requires a broad perspective that stretches from the submicroscopic to the macropolitical level. However, with robust investment trends in this business sphere, there is a sense that a new generation of cancer gene therapies, harnessing the power of the immune system, could dramatically help in developing long-term cures for patients. Recent in 2017, the U.S. FDA approved a cancer gene therapy made by Novartis to treat blood and bone marrow cancer. Dubbed as a CAR-T therapy, the gene therapy approach has shown remarkable results in patients, in turn ushering in a new era of cancer treatment.

Having endorsed itself as a one of the most remunerative verticals of the overall healthcare fraternity, cancer gene therapy market is practically transforming the way cancer diagnostics is being delivered in the recent years. Triggered by the increasing adoption of innovative genomic technologies such as high-density micro array and NGS, the global cancer gene therapy market has been witnessing consequential transformation in the product and price trends. The rapidly rising prevalence of cancer and the growing quest to come up with a significant diagnosis treatment have fortified the demand for cancer gene therapy industry across the globe. According to the statistics reported by the World Health Organization, cancer accounted for over 8.8 million deaths in 2015 and over 14 million new cases were registered in 2012. The number of new cases is further expected to rise by 70% over the next 20 years, making cancer the second most leading cause of death globally.

For More Info: https://empowerednews.net/author/gminsights/

About Us:
Marketstudyreport.com allows you to manage and control all corporate research purchases to consolidate billing and vendor management. You can eliminate duplicate purchases and customize your content and license management.

Contact Us:
Market Study Report
4 North Main Street,
Selbyville, Delaware 19975
USA
Phone: 1-302-273-0910
US Toll Free: 1-866-764-2150
Email: sales@marketstudyreport.com
Web site: https://www.marketstudyreport.com
Blog: https://www.marketstudyreport.com/blog/

This release was published on openPR.